All In Biotech

Drug Trial Radar · NCT03425474

Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy

A Phase Ⅲ, Multicentre, Randomized, Single-blinded Study to Evaluate the Safety and Efficacy of the Sedation for Remimazolam or Propofol in Patients Undergoing Diagnostic Upper GI Endoscopy

Last checked: Nov 20, 2026Latest source record: Feb 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 378 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

378

Actual

Start

Sep 1, 2017

Primary completion

Nov 10, 2017

Study completion Nov 10, 2017

Sponsor

Sponsor type
Industry
First posted
Feb 7, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of the sedation for Remimazolam or Propofol in patients undergoing diagnostic upper GI endoscopy.

Conditions

  • Sedation

Interventions

  • Remimazolam TosilateDrug

    Initial dose plus supplemental doses as necessary

  • PropofolDrug

    Initial dose plus supplemental doses as necessary

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. rate of successful sedationTime frame: approximately 3 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical trial Ethnics Committee of Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.